Association of C-reactive protein and Interleukin-6 single nucleotide polymorphisms with preterm labour: results of a pilot study

Akira Sato^{1,2*}, Hiroshi Miura¹, Yohei Onodera¹, Hiromitsu Shirasawa¹, Saeko
Kameyama¹, Akiko Fujishima¹, Yuko Kikuti³, Mayumi Goto¹, Toshiharu Sato¹, Yukihiro
Terada¹

¹Department of obstetrics and gynaecology, Akita University Hospital, Hondo, Akita,
Japan

²Department of obstetrics, Akita Red Cross Hospital, Aza Nashirozawa Saruta
Kamikitade, Japan

³Central laboratory Division, Akita University Hospital, Hondo, Akita, Japan

*Corresponding author

Email: satoa@doc.med.akita-u.ac.jp

Abstract

Preterm labour (PTL) can be described as an inflammatory event. C-reactive protein (CRP) and Interleukin-6 (IL-6) are key members of the innate immune response that play major roles in inflammation. The main objective of this case-control study was to determine the association of specific CRP and IL-6 polymorphisms with PTL. The study was carried out in a total of 31 Japanese women with PTL and 28 control women with normal pregnancy. Four SNPs in the CRP gene (rs1800947, rs3091244, rs2794521, and rs3093059) and two SNPs in the IL-6 gene (rs2097677 and rs1800795) were genotyped using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Biochemical parameters were assayed and cervical length measurements were performed with ultrasound sonography. There were no significant differences in inflammatory markers, including white blood cell count, CRP, neutrophil elastase in cervical mucous, and foetal fibronectin in vaginal discharge, between the PTL and control groups. The frequency of rs1800947 minor allele (G) was significantly higher in the PTL group than in the control group. This finding has not been previously reported. We suggest that mutations in rs1800947 may lead to PTL. Thus, the rs1800947 SNP may be useful as a genetic marker for PTL risk assessment in pregnant women.

Introduction

Preterm birth remains the major cause of neonatal morbidity and mortality. PTL may have several causes. One of the most convincing hypotheses is that, as in full-term labour[1], PTL may be the result of an inflammatory reaction. Before the onset of labour, a pro-inflammatory condition can be induced in reproductive tissues such as the myometrium, cervix, and decidua. This condition is characterized by pro-inflammatory cytokines such as IL-6 and -8, and the infiltration of monocytes and macrophages. Presumably, the inflammatory reaction may play a role in the transition of the myometrium from a quiescent to a contractile state. Infection as well as uterine hyperextension and bleeding in the contractile state could trigger the pathological contraction of the uterus, leading to PTL.

C-reactive protein (CRP), which plays an important role in innate immunity, is an acute reaction-related protein produced by the liver in response to IL-6. A genome-wide association study in Japanese subjects revealed the association between serum CRP levels and a single nucleotide polymorphism (SNP) in the promoter region of IL-6 [2].

Meanwhile, CRP polymorphisms have been associated with various kinds of inflammatory diseases, such as bacterial infections [3,4], heart disorders [5–10], and malignant tumours [11–14]. Specific SNPs have previously been linked to preterm birth

and labour [15,16]. However, there are only a few reports on the association between IL-6 SNPs and PTL [17–19], and to the best of our knowledge, none on the association between CRP SNPs and PTL. Our attentions were paid to four SNPs in the CRP gene (rs1800947, rs3091244, rs2794521, and rs3093059) and two SNPs in the IL-6 gene (rs2097677 and rs1800795) in the reason why rs1800947, rs3091244, and rs2794521 associated with CRP level in bacterial infection [4], rs2097677 and rs3093059 associated with serum CRP level in a genome-wide association study in Japanese [2], and IL-6 rs1800795 associated with preterm birth [19] were reported previously.

Thus, the purpose of this study was to examine the association of specific CRP and IL-6 polymorphisms with PTL. Our findings suggest that mutations in rs1800947, a CRP SNP, may lead to PTL. Based on these findings, we propose that rs1800947 could be used as a genetic marker for PTL risk assessment in pregnant women.

Materials and Methods

Ethics statement and study subjects

The study protocol was approved by the institutional ethics committee of Akita University of Medicine (Approval number: 1431) and written informed consent was obtained from all participants.

This study was conducted in Akita prefecture at Akita University Hospital between

March 2017 and December 2019. This is a case-control study carried out in a total of 31 Japanese women with PTL and 28 control women with normal pregnancy. The diagnosis of PTL was based on clinical criteria of regular uterine contractions accompanied by a change in cervical dilation, effacement, or both, or initial presentation with regular contractions and cervical dilation of at least 2 cm at 22–36 weeks of gestation [20]. Blood sampling, cervical and vaginal sampling, and transvaginal ultrasound examination were performed when PTL was diagnosed. In the control group, these samplings and measurements were performed at 26–28 weeks of gestation on periodical medical examination.

Genotyping analysis

Fresh blood was collected in EDTA tubes and subjected to density gradient centrifugation using Leuco Spin Medium (pluriSelect Life Science, Leipzig, Germany). After samples were centrifuged for 30 minutes at 1000g at room temperature, the layer corresponding to peripheral blood mononuclear cells (PBMCs) was collected and stored at –80 °C until use for SNP analysis. Genomic DNA was extracted from PBMCs using QIAamp DNA Mini Kit (QIAGEN, Germany). Four SNPs in the CRP gene (rs1800947, rs3091244, rs2794521, and rs3093059) and two SNPs in the IL-6 gene (rs2097677 and rs1800795) were genotyped in all samples using a polymerase chain reaction-restriction

108 fragment length polymorphism (PCR-RFLP) assay. The primer sequences are shown in
109 Table 1. PCR reactions were performed in a total volume of 50 µl containing 50 ng
110 genomic DNA, 3 µl of each primer (0.6 µM), 200 µM of each dNTP, 10× PCR buffer
111 for KOD-Plus-Ver.2 (TOYOBO, Japan), 1.5 mM MgSO₄ and 1.0 U of KOD-Plus-
112 (TOYOBO, Japan). The amplification was carried out with an initial denaturation step
113 at 94 °C for 2 min, followed by 30 cycles of 30 seconds at 55 °C and 60 seconds at
114 68 °C. An ABI Prism 3130xl Genetic Analyzer (Applied Biosystems) was used to
115 sequence the PCR products. BEX Co., Ltd. cooperated in the genotyping of these SNPs
116 throughout the whole process.

117 Table1 Primer sequences for the detection of CRP and IL-6 gene polymorphisms.

	dbSNP ID	Allele (D/d)*	Primer	Sequence
CRP gene	rs1800947	C/G	Forward	TGCCTCCACTTCTACACGGAAC
			Reverse	GGTTTGGTGAACACTTCGCCT
	rs3091244	G/A,T	Forward	GACTCTACTACAAAGGATACGG
	rs2794521	T/C	Reverse	CCTTTGGAAAAGATGTATTCGG
	rs3093059	A/G		
IL-6	rs2097677	G/A	Forward	TTCCGCTAGTCAGTCCCATC

gene			Reverse	TTCGGCCACAAATTCAGTAGG
	rs1800795	G/C	Forward	AGGAAGAGTGGTTCTGCTTC
			Reverse	TGGAGGGGAGATAGAGCTTC

118 Primer sequences for the detection of CRP and IL-6 gene polymorphisms.

119 * Major/minor allele, major and minor alleles are denoted by D and d, respectively.

120 **Biochemical parameters and cervical length measurements**

121 Serum CRP levels and white blood cell counts (WBC) were obtained in the main
122 laboratory by a standard laboratory method. The samples of cervical fluid were obtained
123 with cotton swab placed in the endocervical canal and were mixed and diluted with
124 phosphate buffer, and the extracted buffer was filtrated. The concentration of neutrophil
125 elastase (NE) in sample fluid was determined using a latex agglutination immunoassay
126 kit (Sanwa Kagaku Co., Nagoya, Japan)[21]. Samples of foetal fibronectin (FF) were
127 obtained by taking a cotton swab from posterior vaginal fornix. The concentration of FF
128 in the sample fluid was determined using an enzyme-linked immunosorbent assay kit
129 (Sekisui Medical Co., Tokyo, Japan)[22]. The cut-off points of NE and FF were 1.60
130 µg/mL and 50 ng/ml, respectively. SRL Co., Ltd. cooperated on NE and FF
131 measurements. All cervical length measurements were carried out according to the
132 guidelines of the Foetal Medicine Foundation [23]. Immediately after delivery, 1–2 ml

blood from an umbilical cord artery was taken in a heparin syringe and examined with the laboratory blood gas analyser (ABL80FLEX, RADIOMETER Co., Japan).

Statistical analysis

All data were analysed using the statistical software package JMP 12.2.0 (SAS Institute Inc, Cary, NC, USA). Continuous variables are presented as means $\pm$ standard deviations or median (interquartile range) and categorical variables are presented as fraction. Univariate analysis used student's t-test, Wilcoxon-rank sum test (if variable was not normally distributed), Chi squared test, or Fisher's exact test as appropriate. Normality was assessed using the Shapiro-Wilk test. Odds ratios with 95% confidence intervals for the genotypes were calculated using Chi squared test, or Fisher's exact test. All tests are two sided and p values less than 0.05 were considered statistically significant. Genotype frequencies of all SNPs were tested for Hardy-Weinberg equilibrium (HWE) by chi square test.

Results

Demographic and clinical parameters of the PTL and control groups are shown in Table 2. A significant difference in cervical length was observed between the PTL and control groups ($p < 0.001$). In contrast, no significant differences in CRP levels were observed between the two groups. The frequencies of positive NE and FF were not

151 significantly different between the two groups.

152 Table 2 Comparison of demographic and clinical parameters between the PTL and

153 Control groups.

	PTL (N=31)	Control (N=28)	p-values
Maternal age (years)	33.0±4.92	33.9±5.28	0.486
Primiparous/Multiparous	15/16	11/17	0.601
Primigravid/Multigravid	22/9	15/13	0.189
History of premature delivery	5/26	4/24	1.000
GA at examination *(weeks)	27(26-28)	27(26-27)	0.180
WBC (/ μ L)	7958±1447	8689±1914	0.101
CRP (mg/dL)	0.15(0.08-0.33)	0.13(0.06-0.22)	0.347
Cervical length (mm)	27.5±9.81	49.2±11.4	< 0.001
PMNE (negative/positive)	15/16	14/14	1.000
Fibronectin	29/2	28/0	0.492

(negative/positive)			
---------------------	--	--	--

*GA at examination: gestational age at blood and vaginal sampling and ultrasound measurement. Maternal age, WBC, and Cervical length are presented as means $\pm$ standard deviation. GA at examination and CRP are presented as median (interquartile range). All categorical variables are presented as fraction.

158

Perinatal and neonatal parameters are presented in Table 3. Gestational age at delivery was significantly lower in the PTL group ($p < 0.05$). Mode of delivery, neonatal body weight, sex, Apgar Score, and pH of the umbilical artery were not significantly different between the two groups.

Table 3 Comparison of perinatal and neonatal data

	PTL (N=31)	Control (N=28)	p-values
GA at delivery (weeks)	37(36-37)	39(38-40)	< 0.001
Mode of delivery (vaginal/cesarean)	21/10	18/10	0.790
Neonatal Weight	2792(2542-3022)	2895(2752-3086)	0.054
Male/Female	20/11	11/17	0.069
Apgar Score			
1 minutes			
0-3	2	0	0.742
4-6	1	1	
7-10	28	27	
5 minutes			
0-3	0	0	

4–6	1	0	1.000
7–10	30	28	
pH of Umbilical Artery	7.31±0.067	7.32±0.057	0.676

164 *GA at examination: gestational age at delivery.

165 GA at delivery and pH of Umbilical artery are presented as means± standard deviation.

166 Neonatal weight is presented as median (interquartile range). All categorical variables
167 are presented as fraction.

168

169 Genotype and allele distribution of candidate SNPs are described in Table 4.

170 Rs1800947 in the PTL group (MAF0.19, p<0.001) and rs3091244 in both the PTL
171 (MAF0.22, p<0.001) and control (MAF0.28, p<0.001) groups were deviated from HWE,
172 while the other SNPs were in HWE in both groups. All participants of both groups had
173 GG genotype of IL-6 rs1800795. A significant difference was observed in the genotype
174 distribution of rs1800947 between the PTL and control groups. Specifically, the
175 frequency of the minor G allele was significantly higher in the PTL group (p<0.05).

176 Table 4 Genotypes and alleles distribution of CRP rs1800947, rs3091244, rs2794521,
177 and 3093059, and IL-6 rs2097677, and rs1800795 polymorphisms in the PTL and
178 Control groups.

SNPs (D/d) *	PTL(N=31)	Control(N=28)	OR(95%CI)	p-values
--------------	-----------	---------------	-----------	----------

rs1800947	HWE	HWE		
(C/G)	p<0.001	p=1.000		
	MAF 0.19	MAF 0		
CC	27	28	1.000(Ref)	
CG	2	0	-	0.157
GG	2	0	-	0.157
CG+GG	4	0	-	0.049
Allele				
C	56	56	1.000(Ref)	
G	6	0	-	0.017
rs3091244	HWE	HWE		
(G/T, A)	p<0.001	p<0.001		
	MAF 0.22	MAF 0.28		
GG	17	15	1.000(Ref)	
GT	9	8	0.993(0.305-3.226)	0.990
GA	5	2	0.453(0.076-2.690)	0.376
TT	0	2	-	0.145
AT	0	1	-	0.295

GT+GA+TT+AT	14	13	0.950(0.341-2.650)	0.922
Allele				
G	48	40	1.000(Ref)	
T	9	13	0.577(0.227-1.674)	0.252
A	5	3	0.720(0.162-3.200)	0.665
rs2794521 (T/C)	HWE p=0.230 MAF 0.17	HWE p=0.604 MAF 0.08		
TT	20	23	1.000(Ref)	
TC	11	5	0.395(0.117-1.332)	0.128
Allele				
T	51	51	1.000(Ref)	
C	11	5	0.455(0.147-1.402)	0.163
rs3093059 (A/G)	HWE p=0.344 MAF 0.14	HWE p=0.603 MAF 0.23		
AA	22	17	1.000(Ref)	
AG	9	9	0.773(0.251-2.368)	0.652

GG	0	2	-	0.119
AG+GG	9	11	0.632(0.214-1.871)	0.406
Allele				
A	53	43	1.000(Ref)	
G	9	13	0.562(0.219-1.438)	0.226
rs2097677 (G/A)	HWE p=0.076 MAF 0.24	HWE p=0.890 MAF 0.17		
GG	16	19	1.000(Ref)	
GA	15	8	0.449(0.152-1.330)	0.145
AA	0	1	-	0.364
Allele				
G	47	46	1.000(Ref)	
A	15	10	0.681(0.278-1.671)	0.400

179 *Major/minor allele, major and minor alleles are denoted by D and d, respectively.

180 OR: Odds ratio. CI : Confidence interval. HWE: Hardy-Weinberg equilibrium. MAF:

181 Minor allele frequency.

182 All participants of both groups had GG genotype of IL-6 rs1800795.

183

184 **Discussion**

185 In this study, we did not find significant differences in WBC and serum CRP levels,
186 which are common markers of inflammation and bacterial infection, between the PTL
187 and control groups. These results are consistent with the fact that pregnant women
188 experiencing PTL often show no signs of clinical inflammation or infection. Moreover,
189 no significant differences in NE and FF, which are local inflammatory markers in the
190 uterus, cervix, and vagina, were found between the two groups. Previous reports have
191 already indicated that their efficacy as PTL markers is controversial [24-27]. Regarding
192 perinatal prognosis, the gestational age at delivery was significantly lower in the PTL
193 group than in the control group.

194 The examination of four candidate SNPs in the CRP gene and two candidate SNPs in
195 the IL-6 gene that are associated with CRP production indicated that the frequency of
196 rs1800947 minor G allele in the CRP gene was significantly higher in the PTL group.
197 The human CRP gene is located on chromosome 1q21–23, spanning approximately 1.9
198 kb and containing two exons. Rs1800947 is a synonymous coding polymorphism
199 located on exon 2 of the CRP gene, which was reported for the first time by Cao et al.
200 [28]. Subsequently, various diseases have been associated with rs1800947, such as

coronary artery disease [5,6], myocardial infarction [7–10], cerebrovascular
ischemia-related disease [29–31], prostate cancer [12,13], colorectal cancer [14],
diabetes [32], and depression [33]. The association of this SNP with low CRP levels was
also described in myocardial infarction [7], coronary artery bypass surgery [6], coronary
artery disease [5], cerebrovascular ischemia-related disease [31], diabetes [32], prostate
cancer [12], and oesophageal cancer [34]. In this study, we could not statistically
examine CRP levels according to the genotype of each SNP because of the limited
number of study subjects.

CRP was discovered as a protein bound to phosphocholine, which is a kind of
phospholipid present in the pneumococcal surface. CRP is a representative acute
reaction-related protein that increases in the blood during inflammation, infection, and
tissue injury. When CRP binds to various ligands such as phosphocholine or
polycationic molecules, the classical complement pathway can be activated.
Furthermore, CRP reinforces the production of inflammatory cytokines and tissue
factors (TFs), and the expression of plasminogen activator-1 (PAI-1) in macrophages,
smooth-muscle cells, and vascular endothelial cells.

According to previous reports, mutations in CRP rs1800947 could be involved in the
occurrence and development of diseases because CRP plays a key role in innate

immunity. Multiple factors such as environmental agents could induce these diseases in the presence of a particular SNP mutation. Given our results, we hypothesize that the SNP mutation in the CRP gene could reinforce the production of chemical mediators such as IL-6 by macrophages, which may lead to a pro-inflammatory state in the myometrium and decidua that induces labour.

IL-6 is produced by monocytes, macrophages, and endothelial cells. The relationship between IL-6 and PTL has been extensively described [35-47]. IL-6 increases the expression of myometrial oxytocin receptor and promotes oxytocin secretion, increasing the reactivity of oxytocin [1, 48]. Thus, IL-6 may initiate the pathogenesis of PTL. In this study, we did not observe significant differences in the frequencies of alleles in the IL-6 rs2097677 and rs1800795 SNPs. Adam et al. reported no significant impact of rs1800795 on preterm labour with rupture [17]. Felix et al. reported no significant association of rs1800795 with preterm birth in a study of obstetrical complications in 1,626 pregnant women [18]. Conversely, Digna et al. described rs1800795 as one of the significantly relevant gene sites in association with preterm birth [19]. In this study, the results on rs2097677 and rs1800795 were consistent with the former two reports.

One limitation of this study was the deviation of rs1800947 from HWE, which indicated the possibility of structured subjects in this study. Other limitations include a

small sample size, the lack of serum IL-6 measurements, and the absence of pathological examination of the placenta. A prospective observational study should be conducted and will be necessary to increase the number of subjects in the future.

Conclusion

An association between the rs1800947 minor G allele and PTL was observed in this study. Given the association of rs1800947 with other diseases, we suggest that PTL may occur as a result of rs1800947 gene mutation. Thus, rs1800947 could be used as a genetic marker for PTL risk assessment in pregnant women.

Acknowledgments

The authors thank the participants and staff for their participation in the study. We would like to thank Editage (www.editage.com) for English language editing.

References

1. Sivarajasingam SP, Imami N, Johnson MR. Myometrial cytokines and their role in the onset of labour. J Endocrinol;Volume 231: R101–R119.
doi:[10.1530/JOE-16-0157](https://doi.org/10.1530/JOE-16-0157).
2. Okada Y, Takahashi A, Ohmiya H, Kumasaka N, Kamatani Y, Hosono N, et al. Genome-wide association study for C-reactive protein levels identified pleiotropic associations in the IL6 locus. Hum Mol Genet. 2011;20:6: 1224-1231.

- 255 doi:[10.1093/hmg/ddq551](https://doi.org/10.1093/hmg/ddq551), PubMed: [21196492](https://pubmed.ncbi.nlm.nih.gov/21196492/).
- 256 3. Nasr A, Allam G, Al-Zahrani A, Alsulaimani A. Neonatal infections in Saudi Arabia:
- 257 association with C-reactive protein, CRP -286(C>T>A) gene polymorphism and IgG
- 258 antibodies. BMC Immunol. 2013;14: 38. Available:
- 259 <http://www.biomedcentral.com/1471-2172/14/38>. doi:[10.1186/1471-2172-14-38](https://doi.org/10.1186/1471-2172-14-38),
- 260 PubMed: [23941472](https://pubmed.ncbi.nlm.nih.gov/23941472/).
- 261 4. Mölkanen T, Rostila A, Ruotsalainen E, Alanne M, Perola M, Jarvinen A. Genetic
- 262 polymorphism of the C-reactive protein (CRP) gene and a deep infection focus
- 263 determine maximal serum CRP level in Staphylococcus aureus bacteremia. Eur J
- 264 Clin Microbiol Infect Dis. 2010;29: 1131-1137. doi:[10.1007/s10096-010-0978-z](https://doi.org/10.1007/s10096-010-0978-z),
- 265 PubMed: [20552244](https://pubmed.ncbi.nlm.nih.gov/20552244/).
- 266 5. Grammer TB, März W, Renner W, Böhm BO, Hoffmann MM. C-reactive protein
- 267 genotypes associated with circulating C-reactive protein but not with angiographic
- 268 coronary artery disease: the LURIC study. Eur Heart J. 2009;30: 170–182.
- 269 doi:[10.1093/eurheartj/ehn191](https://doi.org/10.1093/eurheartj/ehn191), PubMed: [18499652](https://pubmed.ncbi.nlm.nih.gov/18499652/).
- 270 6. Perry TE, Muehlschlegel JD, Liu KY, Fox AA, Collard CD, Body SC, et al.
- 271 C-Reactive protein gene variants are associated with postoperative C-reactive

- 272 protein levels after coronary artery bypass surgery. BMC Med Genet. 2009;10: 38.
- 273 doi:[10.1186/1471-2350-10-38](https://doi.org/10.1186/1471-2350-10-38). PubMed: [19426506](https://pubmed.ncbi.nlm.nih.gov/19426506/).
- 274 7. Kolz M, Koenig W, Müller M, Andreani M, Greven S, Illig T, et al. DNA variants,
- 275 plasma levels and variability of C-reactive protein in myocardial infarction
- 276 survivors: results from the AIRGENE study. Eur Heart J. 2008;29: 1250-1258.
- 277 doi:[10.1093/eurheartj/ehm442](https://doi.org/10.1093/eurheartj/ehm442), PubMed: [17956875](https://pubmed.ncbi.nlm.nih.gov/17956875/).
- 278 8. Schulz S, Lüdi H, Lierath M, Schlitt A, Werdan K, Hofmann B, et al. C-reactive
- 279 protein levels and genetic variants of CRP as prognostic markers for combined
- 280 cardiovascular endpoint (cardiovascular death, death from stroke, myocardial
- 281 infarction, and stroke/TIA). Cytokine. 2016;Volume 88; Dec: 71-76.
- 282 doi:[10.1016/j.cyto.2016.08.021](https://doi.org/10.1016/j.cyto.2016.08.021), PubMed: [27580453](https://pubmed.ncbi.nlm.nih.gov/27580453/).
- 283 9. Yazmín HD, Carlos ATZ, Isela JR, Manuel ABG, Manuel ETH, María LLN, et al.
- 284 The role of gene variants of the inflammatory markers CRP and TNF- α in
- 285 cardiovascular heart disease: systematic review and meta-analysis. Int J Clin Exp.
- 286 2015;15:8 (8): 11958-11984.
- 287 10. Hindorff LA, Rice KM, Lange LA, Diehr P, Halder I, Walston J, et al. Common
- 288 variants in the CRP gene in relation to longevity and cause-specific mortality in

289 older adults: the Cardiovascular Health Study. *Atherosclerosis*. 2008;197(2):
 290 922-930. doi:[10.1016/j.atherosclerosis.2007.08.012](https://doi.org/10.1016/j.atherosclerosis.2007.08.012), PubMed: [17888441](https://pubmed.ncbi.nlm.nih.gov/17888441/).

291 11. Kito M, Motoyama S, Fujita K, Miura M, Nanjo H, Sato N, et al. CRP1846C>T
 292 genetic polymorphism is associated with lymph node metastasis and/or severe
 293 lymphatic invasion in endometrial cancer. *Tohoku J Exp Med*. 2015;237: 25-30.
 294 doi:[10.1620/tjem.237.25](https://doi.org/10.1620/tjem.237.25), PubMed: [26310275](https://pubmed.ncbi.nlm.nih.gov/26310275/).

295 12. Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K, et al.
 296 Genetic variation across C-reactive protein and risk of prostate cancer. *Prostate*.
 297 2014;74(10): 1034-1042. doi:[10.1002/pros.22820](https://doi.org/10.1002/pros.22820), PubMed: [24844401](https://pubmed.ncbi.nlm.nih.gov/24844401/).

298 13. Eklund CM, Tammela TLJ, Schleutker J, Hurme M. C-reactive protein haplotype is
 299 associated with high PSA as a marker of metastatic prostate cancer but not with
 300 overall cancer risk. *Br J Cancer*. 2009;100(12): 1846-1851.
 301 doi:[10.1038/sj.bjc.6605081](https://doi.org/10.1038/sj.bjc.6605081), PubMed: [19436291](https://pubmed.ncbi.nlm.nih.gov/19436291/).

302 14. Chen XL, Liao YQ, Liu JR. Genotype CC of rs1800947 in the C-reactive protein
 303 gene may increase susceptibility to colorectal cancer: a meta-analysis. *Asian Pac J*
 304 *Cancer Prev*. 2014;15(6): 2663-2667. doi:[10.7314/apjcp.2014.15.6.2663](https://doi.org/10.7314/apjcp.2014.15.6.2663), PubMed:
 305 [24761881](https://pubmed.ncbi.nlm.nih.gov/24761881/).

- 306 15. Ramos BR, Mendes ND, Tanikawa AA, Amador MA, dos Santos NP, dos Santos SE,
307 et al. Ancestry informative markers and selected single nucleotide polymorphisms in
308 immunoregulatory genes on preterm labor and preterm premature rupture of
309 membranes: a case control study. BMC Preg Childbirth. 2016;16: 30.
310 doi:[10.1186/s12884-016-0823-1](https://doi.org/10.1186/s12884-016-0823-1), PubMed: [26846412](https://pubmed.ncbi.nlm.nih.gov/26846412/).
- 311 16. Sheikh IA, Ahmad E, Jamal MS, Rehan M, Assidi M, Tayubi IA, et al. Spontaneous
312 preterm birth and single nucleotide gene polymorphisms: a recent update. BMC
313 Genomics. 2016;17(suppl 9): 759. doi:[10.1186/s12864-016-3089-0](https://doi.org/10.1186/s12864-016-3089-0), PubMed:
314 [27766960](https://pubmed.ncbi.nlm.nih.gov/27766960/).
- 315 17. Bitner A, Kalinka J. IL- β , IL-6 promoter, TNF- α promoter and IL-1RA gene
316 polymorphisms and the risk of preterm delivery due to preterm premature rupture of
317 membranes in a population of Polish women. Arch Med Sci. 2010;6, 4: 552-557.
318 doi:[10.5114/aoms.2010.14467](https://doi.org/10.5114/aoms.2010.14467), PubMed: [22371799](https://pubmed.ncbi.nlm.nih.gov/22371799/).
- 319 18. Stonek F, Metzenbauer M, Hafner E, Philipp K, Tempfer C. Interleukin 6-174 G/C
320 promoter polymorphism and pregnancy complications: results of a prospective
321 cohort study in 1626 pregnant women. Am J Reprod Immunol. 2008;Volume 59:
322 347–351. doi:[10.1111/j.1600-0897.2007.00577.x](https://doi.org/10.1111/j.1600-0897.2007.00577.x). PubMed: [18336388](https://pubmed.ncbi.nlm.nih.gov/18336388/).
- 323 19. Velez DR, Fortunato SJ, Williams SM, Menon R. Interleukin-6 (IL-6) and

- 324 receptor(IL6-R) gene haplotypes associate with amniotic fluid protein
- 325 concentrations in preterm birth. Hum Mol Genet. 2008;17, 11: 1619-1630.
- 326 doi:[10.1093/hmg/ddn049](https://doi.org/10.1093/hmg/ddn049), PubMed: [18276608](https://pubmed.ncbi.nlm.nih.gov/18276608/).
- 327 20. American College of Obstetricians and Gynecologists' Committee on Practice
- 328 Bulletins—Obstetrics: Practice Bulletin No. 171. Practice Bulletin No. 171:
- 329 Management of Preterm Labor. Obstet Gynecol. 2016;128(4): e155-e164.
- 330 doi:[10.1097/AOG.0000000000001711](https://doi.org/10.1097/AOG.0000000000001711), PubMed: [27661654](https://pubmed.ncbi.nlm.nih.gov/27661654/).
- 331 21. Masuda Y, Maruyama H, Kuraya K. Relationship between granulocyte elastase
- 332 levels and perinatal infections. Gynecol Obstet Invest. 1995;39:162–6.
- 333 22. Lockwood CJ, Senyei AE, Dische MR, Casal D, Shah KD, Thung SN, et al. Fetal
- 334 fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J
- 335 Med. 1991;325(10):669-674.
- 336 23. Available:
- 337 [http://www.fetalmedicine.com/fmf/training-certification/certificates-of-competence/](http://www.fetalmedicine.com/fmf/training-certification/certificates-of-competence/cervical-assessment/)
- 338 [cervical-assessment/](http://www.fetalmedicine.com/fmf/training-certification/certificates-of-competence/cervical-assessment/).
- 339 24. Nakai A, Taniuchi Y, Miyake H, Nakai M, Yokota A, Takeshita T. Increased level of
- 340 granulocyte elastase in cervical secretion is an independent predictive factor for
- 341 preterm delivery. Gynecol Obstet Invest Actions. 2005;60(2):87-91. doi:

- 10.1159/000084839. Epub 2005 Apr 1.
25. Yamada T, Matsubara S, Minakami H, Ohkuchi A, Hiratsuka M, Sato I. Relation between viability of vaginal polymorphonuclear leukocytes and presence of histologic chorioamnionitis. *Acta Obstet Gynecol Scand.* 2009;79:818e23.
26. Son M, Miller ES. Predicting preterm birth: Cervical length and fetal fibronectin. *Semin Perinatol.* 2017; 41(8):445-451. doi:10.1053/j.semperi.2017.08.002. Epub 2017 Sep 19.
27. Berghella V, Saccone G. Fetal fibronectin testing for reducing the risk of preterm birth. *Cochrane Database Syst Rev.* 2019; 29:7(7):CD006843. doi:10.1002/14651858.CD006843.pub3.
28. Cao H, Hegele RA. Human C-reactive protein (CRP) 1059G/C polymorphism. *J Hum Genet.* 2000;45: 100–101. doi:[10.1007/s100380050022](https://doi.org/10.1007/s100380050022), PubMed: [10721674](https://pubmed.ncbi.nlm.nih.gov/10721674/).
29. Chen Z, Yu D, Xu ZW, Li SS, Li XF, Li Jing, et al. C-reactive protein gene polymorphisms and gene-environment interactions in ischaemic stroke. *Neurol Res.* 2015;37(11): 979-984. doi:[10.1179/1743132815Y.0000000053](https://doi.org/10.1179/1743132815Y.0000000053), PubMed: [26004291](https://pubmed.ncbi.nlm.nih.gov/26004291/).
30. Kuhlenbaeumer G, Huge A, Berger K, Kessler C, Voelzke H, Funke H, et al.. Genetic variants in the C-reactive protein gene are associated with microangiopathic ischemic stroke. *Cerebrovasc Dis.* 2010;Volume 30: 476–482.

360 doi:[10.1159/000319021](https://doi.org/10.1159/000319021). PubMed: [20733302](https://pubmed.ncbi.nlm.nih.gov/20733302/).

361 31. Morita A, Nakayama T, Soma M. Association study between C-reactive protein

362 genes and ischemic stroke in Japanese subjects. *Am J Hypertens*. 2006;19(6):

363 593-600. doi:[10.1016/j.amjhyper.2005.11.015](https://doi.org/10.1016/j.amjhyper.2005.11.015), PubMed: [16733231](https://pubmed.ncbi.nlm.nih.gov/16733231/).

364 32. Lee CC, You NC, Song Y, Hsu YH, Manson J, Nathan L, et al. Relation of genetic

365 variation in the gene coding for C-reactive protein with its plasma protein

366 concentrations: findings from the Women's Health Initiative Observational Cohort.

367 *Clin Chem*. 2009;55(2): 351-360. doi:[10.1373/clinchem.2008.117176](https://doi.org/10.1373/clinchem.2008.117176), PubMed:

368 [19095725](https://pubmed.ncbi.nlm.nih.gov/19095725/).

369 33. Halder I, Marsland AL, Cheong J, Muldoon MF, Ferrell RE, Manuck SB.

370 Polymorphisms in the CRP gene moderate an association between depressive

371 symptoms and circulating levels of C-reactive protein. *Brain Behav Immun*.

372 2010;24(1): 160-167. doi:[10.1016/j.bbi.2009.09.014](https://doi.org/10.1016/j.bbi.2009.09.014), PubMed: [19796676](https://pubmed.ncbi.nlm.nih.gov/19796676/).

373 34. Motoyama S, [Miura M](#), Hinai Y, [Maruyama K](#), Usami S, [Nakatsu T](#), et al.

374 C-reactive protein 1059G>C genetic polymorphism influences serum C-reactive

375 protein levels after esophagectomy in patients with thoracic esophageal cancer. *J Am*

376 *Coll Surg*. 2009;209(4): 477-483. doi:[10.1016/j.jamcollsurg.2009.06.365](https://doi.org/10.1016/j.jamcollsurg.2009.06.365), PubMed:

377 [19801321](https://pubmed.ncbi.nlm.nih.gov/19801321/).

- 378 35. Romero R, Avila C, Santhanam U, Sehgal PB. Amniotic fluid interleukin 6 in
379 preterm labor. Association with infection. *J Clin Invest.* 1990;85:1392–400.
- 380 36. Yoon BH, Romero R, Jun JK, et al. Amniotic fluid cytokines (interleukin-6, tumor
381 necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the
382 development of bronchopulmonary dysplasia. *Am J Obstet Gynecol.* 1997;177:825–
383 30.
- 384 37. Arntzen KJ, Kjollesdal AM, Halgunset J, et al. TNF, IL-1, IL-6, IL-8 and soluble
385 TNF receptors in relation to chorioamnionitis and premature labor. *J Perinat Med.*
386 1998;26:17–26.
- 387 38. Cobo T, Tsiartas P, Kacerovsky M, et al. Maternal inflammatory response to
388 microbial invasion of the amniotic cavity: analyses of multiple proteins in the
389 maternal serum. *Acta Obstet Gynecol Scand.* 2013;92:61–8.
- 390 39. Romero R, Sepulveda W, Kenney JS, et al. Interleukin 6 determination in the
391 detection of microbial invasion of the amniotic cavity. *Ciba Found Symp.*
392 1992;167:205–20; discussion 220–3.
- 393 40. Romero R, Yoon BH, Kenney JS, et al. Amniotic fluid interleukin-6 determinations
394 are of diagnostic and prognostic value in preterm labor. *Am J Reprod Immunol.*
395 1993;30:167–83.

- 396 41. Romero R, Yoon BH, Mazor M, et al. The diagnostic and prognostic value of
397 amniotic fluid white blood cell count, glucose, interleukin-6, and gram stain in
398 patients with preterm labor and intact membranes. *Am J Obstet Gynecol.*
399 1993;169:805–16.
- 400 42. Romero R, Yoon BH, Mazor M, et al. A comparative study of the diagnostic
401 performance of amniotic fluid glucose, white blood cell count, interleukin-6, and
402 gram stain in the detection of microbial invasion in patients with preterm premature
403 rupture of membranes. *Am J Obstet Gynecol.* 1993;169:839–51.
- 404 43. Allbert JR, Naef 3rd RW, Perry Jr. KG, et al. Amniotic fluid interleukin-6 and
405 interleukin-8 levels predict the success of tocolysis in patients with preterm labor. *J*
406 *Soc Gynecol Investig.* 1994;1:264–8.
- 407 44. Hsu CD, Meaddough E, Aversa K, et al. Elevated amniotic fluid levels of leukemia
408 inhibitory factor, interleukin 6, and interleukin 8 in intra-amniotic infection. *Am J*
409 *Obstet Gynecol.* 1998;179:1267–70.
- 410 45. Yoon BH, Romero R, Kim KS, et al. A systemic fetal inflammatory response and
411 the development of bronchopulmonary dysplasia. *Am J Obstet Gynecol.*
412 1999;181:773–9.
- 413 46. Rogers BB, Alexander JM, Head J, et al. Umbilical vein interleukin-6 levels

414 correlate with the severity of placental inflammation and gestational age. Hum
 415 Pathol. 2002;33:335–40.

416 47. Jacobsson B, Mattsby-Baltzer I, Hagberg H. Interleukin-6 and interleukin-8 in
 417 cervical and amniotic fluid: relationship to microbial invasion of the chorioamniotic
 418 membranes. BJOG. 2005;112:719–24.

419 48. Friebe-Hoffmann U, Chiao JP, Rauk PN. Effect of IL-1beta and IL-6 on oxytocin
 420 secretion in human uterine smooth muscle cells. Am J Reprod Immunol. 2001;46:
 421 226–231. doi:[10.1034/j.1600-0897.2001.d01-6.x](https://doi.org/10.1034/j.1600-0897.2001.d01-6.x), PubMed: [11554696](https://pubmed.ncbi.nlm.nih.gov/11554696/).